Vator Securities advises Magle Chemoswed Holding in connection with its public offer to the shareholders of Amniotics
The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes two operational areas.
Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products.
read moreVator Securities acts as Sole Bookrunner in LifeClean International 16 MSEK Directed Issue
LifeClean International offers sustainable disinfection, sanitation and cleaning solutions that address several of our biggest challenges, such as antimicrobial resistance, contamination and PFAS pollution. Among other things, LifeClean is behind the world’s first climate-neutral chemical production, the world’s richest detergent and a unique, patented and more environmentally friendly chemical formula based on chlorine dioxide.
The chemical technology is the basis for a proven effective method for PFAS sanitation and is also verified as a spore-, fungus-, biofilm-, bacteria- and virus-killing surface disinfection. The Company operates two production facilities in Sweden, certified according to ISO 13485, ISO 14001 and ISO 9001.
read moreVator Securities acts as Sole Bookrunner in ChromoGenics 16 MSEK Directed Issue
ChromoGenics is a proptech company that produces smart dynamic glass, improving indoor environment and well-being while reducing energy consumption, operational costs, and climate impact in real estate. The product, ConverLight® dynamic glass, is based on a unique patented technology from the Ångström Laboratory in Uppsala, where electrochromic coatings are sputtered onto plastic films.
The result is a dynamic foil that can be laminated into glass, providing effective sun protection in buildings and reducing environmental impact in production, transportation, and usage. The dynamic foil is easy to transport and can be applied by local partners in the glass industry, avoiding the need for long-distance shipments of bulky glass.
read moreVator Securities acts as Sole Global Coordinator in Kancera 122 MSEK Rights Issue
Kancera is developing a new class of small molecule drugs targeting the fractalkine axis. Kancera’s main focus is to develop its candidate drugs for treatment of severe inflammatory diseases and cancer that currently lack effective treatments.
The company is a leader in drug development of small molecule fractalkine blockers. Kancera is developing two drug candidates with the same mode of action; the CX3CR1 antagonists KAND567 and KAND145.
read more